These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 26362898)

  • 1. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
    Kuhle J; Hardmeier M; Disanto G; Gugleta K; Ecsedi M; Lienert C; Amato MP; Baum K; Buttmann M; Bayas A; Brassat D; Brochet B; Confavreux C; Edan G; Färkkilä M; Fredrikson S; Frontoni M; D'Hooghe M; Hutchinson M; De Keyser J; Kieseier BC; Kümpfel T; Rio J; Polman C; Roullet E; Stolz C; Vass K; Wandinger KP; Kappos L;
    Mult Scler; 2016 Apr; 22(4):533-43. PubMed ID: 26362898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.
    Kappos L; Weinshenker B; Pozzilli C; Thompson AJ; Dahlke F; Beckmann K; Polman C; McFarland H; ;
    Neurology; 2004 Nov; 63(10):1779-87. PubMed ID: 15557490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
    Panitch H; Miller A; Paty D; Weinshenker B;
    Neurology; 2004 Nov; 63(10):1788-95. PubMed ID: 15557491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
    Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
    J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.
    Tur C; Montalban X; Tintoré M; Nos C; Río J; Aymerich FX; Brieva L; Téllez N; Perkal H; Comabella M; Galán I; Calle D; Sastre-Garriga J; Rovira A
    Arch Neurol; 2011 Nov; 68(11):1421-7. PubMed ID: 22084124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
    Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS.
    Kappos L; Polman C; Pozzilli C; Thompson A; Beckmann K; Dahlke F;
    Neurology; 2001 Dec; 57(11):1969-75. PubMed ID: 11739811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
    Ebers GC; Traboulsee A; Li D; Langdon D; Reder AT; Goodin DS; Bogumil T; Beckmann K; Wolf C; Konieczny A;
    J Neurol Neurosurg Psychiatry; 2010 Aug; 81(8):907-12. PubMed ID: 20562430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b.
    Sormani MP; Bruzzi P; Beckmann K; Wagner K; Miller DH; Kappos L; Filippi M;
    Neurology; 2003 May; 60(9):1462-6. PubMed ID: 12743232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
    Goodin DS; Reder AT; Traboulsee AL; Li DK; Langdon D; Cutter G; Cook S; O'Donnell T; Kremenchutzky M; Oger J; Koelbach R; Pohl C; Wicklein EM;
    Mult Scler; 2019 May; 25(6):837-847. PubMed ID: 29761737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
    Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis].
    Zimmermann C; Walther EU; Goebels N; Lienert C; Kappos L; Hartung HP; Hohlfeld R
    Nervenarzt; 1999 Aug; 70(8):759-63. PubMed ID: 10483579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
    Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Russo CV; Triassi M; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2016 Nov; 10():90-96. PubMed ID: 27919507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
    Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A
    JAMA Neurol; 2015 Dec; 72(12):1458-65. PubMed ID: 26458124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
    Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Metzig C; Bauer L; Lanius V; Sandbrink R; Pohl C;
    Lancet Neurol; 2009 Nov; 8(11):987-97. PubMed ID: 19748319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.